{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:32:37Z","timestamp":1782743557044,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.semradonc.2024.07.011","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T06:03:19Z","timestamp":1733983399000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Radiotherapy in Hematologic Malignancies in Children, Adolescents, and Young Adults"],"prefix":"10.1016","volume":"35","author":[{"given":"Sarah A.","family":"Milgrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.semradonc.2024.07.011_bib0001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.6004\/jnccn.2023.0040","article-title":"Adolescent and young adult (AYA) oncology, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Bhatia","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0002","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ijc.2910080203","article-title":"Epidemiologic patterns of Hodgkin's disease","volume":"8","author":"Correa","year":"1971","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semradonc.2024.07.011_bib0003","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.epirev.a036276","article-title":"Epidemiology of Hodgkin's disease","volume":"6","author":"Grufferman","year":"1984","journal-title":"Epidemiol Rev"},{"issue":"9","key":"10.1016\/j.semradonc.2024.07.011_bib0004","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.bjc.6603999","article-title":"Hodgkin's lymphoma and infection: findings from a UK case-control study","volume":"97","author":"Newton","year":"2007","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2024.07.011_bib0005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/ijc.2910190502","article-title":"Epidemiology of hodgkin's disease in the young","volume":"19","author":"Gutensohn","year":"1977","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0006","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJM198101153040302","article-title":"Childhood social environment and Hodgkin's disease","volume":"304","author":"Gutensohn","year":"1981","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0007","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<977::AID-IJC10>3.0.CO;2-2","article-title":"Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years","volume":"72","author":"Westergaard","year":"1997","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0360-3016(94)90143-0","article-title":"Hodgkin's disease in the very young","volume":"28","author":"Cleary","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0950-3536(96)80018-7","article-title":"The epidemiology of Hodgkin's disease","volume":"9","author":"Glaser","year":"1996","journal-title":"Baillieres Clin Haematol"},{"issue":"7","key":"10.1016\/j.semradonc.2024.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1055-9965.1236.13.7","article-title":"Number of siblings and risk of Hodgkin's lymphoma","volume":"13","author":"Chang","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0011","first-page":"235","article-title":"Ethnic patterns of Hodgkin's disease incidence among children and adolescents in the United States, 1973-82","volume":"76","author":"Spitz","year":"1986","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.semradonc.2024.07.011_bib0012","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3109\/10428194.2010.525724","article-title":"Comparing adult and pediatric Hodgkin lymphoma in the surveillance, epidemiology and end results program, 1988-2005: an analysis of 21 734 cases","volume":"51","author":"Bazzeh","year":"2010","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0013","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","article-title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials","volume":"9","author":"Kahn","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0014","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin's disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0015","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/1097-0142(197212)30:6<1495::AID-CNCR2820300613>3.0.CO;2-I","article-title":"A decade of combination chemotherapy of advanced Hodgkin's disease","volume":"30","author":"DeVita","year":"1972","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.semradonc.2024.07.011_bib0016","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.1986.4.9.1295","article-title":"Twenty years of MOPP therapy for Hodgkin's disease","volume":"4","author":"Longo","year":"1986","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0017","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.1997.15.6.2247","article-title":"Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian pediatric Hodgkin's disease group","volume":"15","author":"Schellong","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.1987.5.1.27","article-title":"Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy","volume":"5","author":"Santoro","year":"1987","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.semradonc.2024.07.011_bib0019","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-104-6-739","article-title":"Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results","volume":"104","author":"Bonadonna","year":"1986","journal-title":"Ann Intern Med"},{"issue":"13","key":"10.1016\/j.semradonc.2024.07.011_bib0021","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJM198204013061303","article-title":"Alternating drug combinations in the treatment of advanced Hodgkin's disease","volume":"306","author":"Santoro","year":"1982","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semradonc.2024.07.011_bib0022","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.2000.18.7.1500","article-title":"Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French society of pediatric oncology study MDH90","volume":"18","author":"Landman-Parker","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2024.07.011_bib0023","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semradonc.2024.07.011_bib0024","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.1999.17.12.3736","article-title":"High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian pediatric Hodgkin's disease study group","volume":"17","author":"Schellong","year":"1999","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.semradonc.2024.07.011_bib0025","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1200\/JCO.2002.03.051","article-title":"Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation","volume":"20","author":"Friedmann","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.semradonc.2024.07.011_bib0026","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.semradonc.2024.07.011_bib0027","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.semradonc.2024.07.011_bib0028","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.semradonc.2024.07.011_bib0029","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.semradonc.2024.07.011_bib0030","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0031","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.semradonc.2024.07.011_bib0032","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-Korholz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0033","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1470-2045(23)00019-0","article-title":"Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study","volume":"24","author":"Mauz-Korholz","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0034","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-Korholz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.semradonc.2024.07.011_bib0035","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.semradonc.2024.07.011_bib0036","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-136422","article-title":"SWOG S1826: a phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.semradonc.2024.07.011_bib0037","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2023-180107","article-title":"Progression-free survival (PFS) and toxicity with nivolumab-AVD compared to brentuximab vedotin-AVD in pediatric advanced stage (AS) classic Hodgkin lymphoma (cHL), results of SWOG S1826","volume":"142","author":"Castellino","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semradonc.2024.07.011_bib0038","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.1999.17.8.2493","article-title":"Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography","volume":"17","author":"Bradley","year":"1999","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2024.07.011_bib0039","doi-asserted-by":"crossref","first-page":"e30452","DOI":"10.1002\/pbc.30452","article-title":"Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0831","volume":"70","author":"Lo","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.semradonc.2024.07.011_bib0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: issues in delineating the radiation field in Hodgkin's disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.011_bib0041","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.semradonc.2024.07.011_bib0042","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.011_bib0043","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"10.1016\/j.semradonc.2024.07.011_bib0044","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2024.07.011_bib0045","doi-asserted-by":"crossref","first-page":"e29600","DOI":"10.1002\/pbc.29600","article-title":"Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy: an updated analysis of more than 10 years of follow-up","volume":"69","author":"Tringale","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.semradonc.2024.07.011_bib0046","doi-asserted-by":"crossref","first-page":"e28941","DOI":"10.1002\/pbc.28941","article-title":"Second tumor risk in children treated with proton therapy","volume":"68","author":"Indelicato","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.semradonc.2024.07.011_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13935","article-title":"Assessment of radiation doses delivered to organs at risk among patients with early-stage favorable hodgkin lymphoma treated with contemporary radiation therapy","volume":"3","author":"Pinnix","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.011_bib0048","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ijrobp.2021.06.030","article-title":"Clinical outcomes confirm conjecture: modern radiation therapy reduces the risk of late toxicity in survivors of hodgkin lymphoma","volume":"111","author":"Milgrom","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2024.07.011_bib0049","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \"butterfly\" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.semradonc.2024.07.011_bib0050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2016.00176","article-title":"Effect of akimbo versus raised arm positioning on breast and cardiopulmonary dosimetry in pediatric Hodgkin lymphoma","volume":"6","author":"Denniston","year":"2016","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.semradonc.2024.07.011_bib0051","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1200\/JCO.20.01186","article-title":"Impact of risk-adapted therapy for pediatric Hodgkin lymphoma on risk of long-term morbidity: a report from the childhood cancer survivor study","volume":"39","author":"Oeffinger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.semradonc.2024.07.011_bib0052","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0053","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.semradonc.2024.07.011_bib0054","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogova","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-Korholz","year":"2007","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.semradonc.2024.07.011_bib0056","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2015.65.3469","article-title":"Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the children's oncology group","volume":"34","author":"Appel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0057","first-page":"187","article-title":"Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy","volume":"86","author":"Zinzani","year":"2001","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.semradonc.2024.07.011_bib0058","first-page":"1258","article-title":"Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients","volume":"87","author":"Zinzani","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0059","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2015.09.017","article-title":"Improved survival with radiation therapy in stage I-II primary mediastinal B cell lymphoma: a surveillance, epidemiology, and end results database analysis","volume":"94","author":"Jackson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.semradonc.2024.07.011_bib0060","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.semradonc.2024.07.011_bib0061","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"17_suppl","key":"10.1016\/j.semradonc.2024.07.011_bib0062","doi-asserted-by":"crossref","first-page":"LBA7505","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA7505","article-title":"Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial","volume":"41","author":"Zucca","year":"2023","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.semradonc.2024.07.011_bib0063","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.21.00920","article-title":"Dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: a multicenter phase II trial","volume":"39","author":"Burke","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.semradonc.2024.07.011_bib0064","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.semradonc.2024.07.011_bib0065","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM199710303371802","article-title":"Treatment of children and young adults with early-stage non-Hodgkin's lymphoma","volume":"337","author":"Link","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0066","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.1999.17.2.456","article-title":"Treatment of localized primary non-Hodgkin's lymphoma of bone in children: a pediatric oncology group study","volume":"17","author":"Suryanarayan","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2024.07.011_bib0067","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/ijc.30576","article-title":"Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013","volume":"140","author":"Mukhtar","year":"2017","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.semradonc.2024.07.011_bib0068","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","article-title":"Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) multicenter trial","volume":"107","author":"Oschlies","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0069","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the international lymphoma radiation oncology group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2024.07.011_bib0070","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the international lymphoma radiation oncology group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.semradonc.2024.07.011_bib0071","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2005.04.033","article-title":"Effective palliation by low dose local radiotherapy for recurrent and\/or chemotherapy refractory non-follicular lymphoma patients","volume":"41","author":"Haas","year":"2005","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0072","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2024.07.011_bib0073","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/1097-0142(19910501)67:9<2262::AID-CNCR2820670909>3.0.CO;2-U","article-title":"Cranial nerve palsy in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma","volume":"67","author":"Ingram","year":"1991","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0074","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"issue":"35","key":"10.1016\/j.semradonc.2024.07.011_bib0075","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.01692","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16","volume":"37","author":"Jeha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2024.07.011_bib0076","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2015.64.2850","article-title":"Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy","volume":"34","author":"Vora","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2024.07.011_bib0077","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/1097-0142(19800415)45:8<2009::AID-CNCR2820450805>3.0.CO;2-A","article-title":"Testicular relapse in childhood acute lymphoblastic leukemia: association with pretreatment patient characteristics and treatment. A report for Childrens Cancer Study Group","volume":"45","author":"Nesbit","year":"1980","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.semradonc.2024.07.011_bib0078","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1200\/JCO.1984.2.8.924","article-title":"Isolated testicular relapse in acute lymphocytic leukemia of childhood: categories and influence on survival","volume":"2","author":"Bowman","year":"1984","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.011_bib0079","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2141.1990.tb07788.x","article-title":"Testicular irradiation in childhood lymphoblastic leukaemia. Medical research council working party on leukemia in childhoods","volume":"75","author":"Eden","year":"1990","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.semradonc.2024.07.011_bib0080","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1002\/cncr.33609","article-title":"Testicular involvement of acute lymphoblastic leukemia in children and adolescents: diagnosis, biology, and management","volume":"127","author":"Nguyen","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0081","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/pbc.20716","article-title":"Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: results of the EORTC CLG Study 58881","volume":"49","author":"Sirvent","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0082","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/pbc.22946","article-title":"Outcome after first relapse in children with acute lymphoblastic leukemia: a report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol","volume":"57","author":"van den Berg","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0083","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","article-title":"Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a pediatric blood and marrow transplant consortium study","volume":"32","author":"Bunin","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0084","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1705923","article-title":"Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases","volume":"41","author":"Satwani","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.semradonc.2024.07.011_bib0085","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3324\/haematol.2020.249458","article-title":"Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children","volume":"106","author":"Dandoy","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.semradonc.2024.07.011_bib0086","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total Body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2024.07.011_bib0087","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2000.18.2.340","article-title":"Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia","volume":"18","author":"Davies","year":"2000","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.semradonc.2024.07.011_bib0088","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2005.03.3373","article-title":"Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study","volume":"24","author":"Barredo","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2024.07.011_bib0089","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12885-018-4432-4","article-title":"Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma","volume":"18","author":"Rogasch","year":"2018","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.semradonc.2024.07.011_bib0090","doi-asserted-by":"crossref","first-page":"e29212","DOI":"10.1002\/pbc.29212","article-title":"Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031","volume":"68","author":"Milgrom","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.semradonc.2024.07.011_bib0091","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/bjh.18734","article-title":"Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: a children's oncology group study","volume":"201","author":"Milgrom","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0092","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.seminhematol.2023.06.005","article-title":"Clinical applications of circulating tumor DNA in Hodgkin lymphoma","volume":"60","author":"Heger","year":"2023","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.semradonc.2024.07.011_bib0093","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2018-07-862607","article-title":"Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma","volume":"133","author":"Opstal-van Winden","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semradonc.2024.07.011_bib0094","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429624000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T13:59:29Z","timestamp":1734011969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429624000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1053429624000626"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.07.011","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Radiotherapy in Hematologic Malignancies in Children, Adolescents, and Young Adults","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2024.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}